Author

Lyudmila Zhukova

Observed names: L G Zhukova, L. G. Zhukova, L. Zhukova, L.G. Zhukova, L.G. Zhukova Zhukova, L. G. Zhukova, Liudmila G. Zhukova, Liudmila G Zhukova, Liudmila G. Zhukova, Liudmila Zhukova, Ludmila G Zhukova, Ludmila G. Zhukova, Ludmila Zhukova, Luidmila Zhukova, Lyudmila G. Zhukova, Zhukova Liudmila, Л. Г. Жукова, Людмила Григорьевна Жукова

Institution: Moscow Clinical Scientific Center

Observed institutions: AstraZeneca (United Kingdom), Institute of Cancer Research, Moscow Clinical Scientific Center, Centre de Recherches en Cancérologie de Toulouse, Russian Cancer Research Center NN Blokhin, Institute of Oncology NN Petrov, Ministry of Health of the Russian Federation, Royal Marsden Hospital, The Christie NHS Foundation Trust

ORCID: 0000-0003-4848-6938

Observed ORCID: 0000-0003-4848-6938

OpenAlex ID: A5074161568

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

2023 · Nicholas C. Turner, Mafalda Oliveira, et al. · New England Journal of Medicine · 787

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

2022 · Jens Huober, Carlos H. Barrios, et al. · Journal of Clinical Oncology · 128

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

2024 · Mafalda Oliveira, Hope S Rugo, et al. · The Lancet Oncology · 43

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

2024 · Teresa Macarulla, Zhenggang Ren, et al. · Journal of Clinical Oncology · 38

Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial

2023 · Nicholas Turner, Mafalda Oliveira, et al. · Cancer Research · 30

IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer.

2023 · Anthony B. El-Khoueiry, Zhenggang Ren, et al. · Journal of Clinical Oncology · 26

Expression of Flt-1 and Flk-1 Receptors for Vascular Endothelial Growth Factor on Tumor Cells as a New Prognostic Criterion for Locally Advanced Breast Cancer

2003 · L. G. Zhukova, N. V. Zhukov, et al. · Bulletin of Experimental Biology and Medicine · 26

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

2024 · H.S. Rugo, M. Oliveira, et al. · ESMO Open · 25

The Gut Microbiota Impacts Gastrointestinal Cancers through Obesity, Diabetes, and Chronic Inflammation

2024 · Konstantin A. Rumyantsev, Vera V. Polyakova, et al. · Life · 15

Практические рекомендации по лекарственному лечению рака молочной железы

2021 · М. Б. Стенина, Л. Г. Жукова, et al. · Malignant tumours · 14

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

2021 · Chris Twelves, Rupert Bartsch, et al. · Clinical Breast Cancer · 12

2021 · Liudmila G. Zhukova, Iuliia I. Andreeva, et al. · Journal of Modern Oncology · 12

187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial

2023 · M. Oliveira, H.S. Rugo, et al. · ESMO Open · 11

Early biomarkers of nephrotoxicity associated with the use of anti‑VEGF drugs

2022 · Natalia Chebotareva, Katerina Grechukhina, et al. · Biomedical Reports · 11

Практические рекомендации по лекарственному лечению рака молочной железы

2021 · С. А. Тюляндин, Л. Г. Жукова, et al. · Malignant tumours · 11

The impact of inhalation versus total intravenous anesthesia on the immune status in patients undergoing breast cancer surgery: a double-blind randomized clinical trial (TeMP)

2024 · Kristina Kadantseva, Valery Subbotin, et al. · Frontiers in Oncology · 8

Application of Multigene Panels Testing for Hereditary Cancer Syndromes

2022 · Airat Bilyalov, Sergey Nikolaev, et al. · Biology · 8

Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

2019 · O. O. Gordeeva, L. G. Zhukova, et al. · Siberian Journal of Oncology · 8

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer

2024 · Nicholas C Turner, Mafalda Oliveira, et al. · Future Oncology · 7

NGAL and KIM-1 as early biomarkers of cisplatin-associated nephrotoxicity.

2023 · Natalia Chebotareva, Lyudmila Zhukova, et al. · Journal of Clinical Oncology · 7

Diagnostic Accuracy of Mammography and Mammoscintigraphy With 99m Tc-mibi in Detection of Minimal Breast Cancer

2017 · Antonina Chernaya, Sergey Kanaev, et al. · Voprosy Onkologii · 7

600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ ERBB2 -Negative Advanced Breast Cancer

2025 · Fatima Cardoso, William Jacot, et al. · JAMA Oncology · 6

Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).

2024 · Anthony B. El-Khoueiry, Zhenggang Ren, et al. · Journal of Clinical Oncology · 6

Russian consensus on prevention, diagnosis and treatment of gastric cancer

2023 · I. E. Khatkov, S. R. Abdulkhakov, et al. · Malignant tumours · 6

Abstract PS17-03: Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial

2024 · Sacha Howell, Hope Rugo, et al. · Cancer Research · 5

Works count: 227

Citation count: 1,430

H-index: 12

I10-index: 15